Stocktoria
FENNEC PHARMACEUTICALS INC. FENC
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2001-06-05
FENNEC PHARMACEUTICALS INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $44.6M | $47.5M | $23.8M | $1.8M | — |
| Gross profit | — | — | $20.0M | $1.4M | — |
| R&D expense | $250,000 | $307,000 | $56,000 | $3.5M | $5.0M |
| Operating income | -$6.3M | $2.6M | -$12.8M | -$22.6M | -$17.2M |
| Income tax | $106,000 | $365,000 | — | $0 | $0 |
| Net income | -$9.7M | -$436,000 | -$16.0M | -$23.7M | -$17.3M |
| EPS (diluted) | $-0.34 | $-0.02 | $-0.60 | $-0.90 | $-0.67 |
| Operating cash flow | -$12.5M | $27.0M | -$17.1M | -$18.1M | -$14.2M |
| Cash & equivalents | $36.8M | $26.6M | $13.3M | $23.8M | $21.1M |
| Total assets | $70.6M | $44.9M | $26.9M | $26.9M | $22.4M |
| Total liabilities | $35.1M | $50.8M | $38.5M | $29.5M | $6.6M |
| Shareholders' equity | $35.5M | -$5.9M | -$11.6M | -$2.6M | $15.8M |
Source: SEC EDGAR filings · CIK 0001211583 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.